EXPO trades 10.1% below Wall Street's consensus target of $72.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EXPO achieves its forward estimates and maintains a stable P/E multiple of 31.8x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Exponent, Inc. (EXPO) has a Wall Street consensus price target of $72.00, based on estimates from 8 covering analysts. With the stock currently trading at $65.41, this represents a potential upside of +10.1%. The company has a market capitalization of $3.17B.
Analyst price targets range from a low of $72.00 to a high of $72.00, representing a 0% spread in expectations. The median target of $72.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EXPO trades at a trailing P/E of 31.6x and forward P/E of 31.8x. The forward PEG ratio of 5.34 reflects a premium valuation. Analysts expect EPS to grow -9.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $66.76, with bear and bull scenarios of $42.06 and $87.97 respectively. Model confidence stands at 47/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ICFIICF International, Inc. | $1.5B | $83.68 | $110.00 | +31.5% | Buy | 11.8x | 13 |
 CRAICRA International, Inc. | $1.0B | $162.02 | $194.00 | +19.7% | Buy | 19.7x | 1 |
 HCIHCI Group, Inc. | $2.2B | $176.12 | $225.00 | +27.8% | Buy | 9.2x | 14 |
 FORRForrester Research, Inc. | $229M | $11.78 | — | — | Hold | 15.2x | 4 |
 FCNFTI Consulting, Inc. | $3.7B | $133.49 | $174.50 | +30.7% | Buy | 14.4x | 13 |
 VRSKVerisk Analytics, Inc. | $22.4B | $171.80 | $225.43 | +31.2% | Hold | 22.3x | 25 |
 EFXEquifax Inc. | $18.2B | $155.32 | $216.92 | +39.7% | Buy | 18.1x | 36 |
 ACNAccenture plc | $112.3B | $183.52 | $200.65 | +9.3% | Buy | 13.2x | 53 |
 BAHBooz Allen Hamilton Holding Corporation | $9.1B | $75.65 | $89.00 | +17.6% | Buy | 12.5x | 22 |
 SAICScience Applications International Corporation | $5.6B | $132.96 | $118.75 | -10.7% | Hold | 13.2x | 18 |
Quick answers to the most common questions about buying EXPO stock.
Exponent, Inc. (EXPO) has a consensus 12-month price target of $72, implying 10.1% upside from $65.41. The 8 analysts covering EXPO see moderate appreciation potential.
EXPO has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $72 implies 10.1% upside from current levels.
EXPO trades at a forward P/E of 31.8266x, representing a moderate valuation. With analysts targeting $72 (10.1% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $72 for EXPO, while the most conservative target is $72. The consensus of $72 represents the median expectation. Our quantitative valuation model projects a bull case target of $88 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EXPO is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EXPO stock forecast based on 8 Wall Street analysts shows a consensus price target of $72, with estimates ranging from $72 (bear case) to $72 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $67, with bear/bull scenarios of $42/$88.
Our quantitative valuation model calculates EXPO's fair value at $67 (base case), with a bear case of $42 and bull case of $88. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 47/100.
EXPO trades at a forward P/E ratio of 31.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 31.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on EXPO, with a "Buy" consensus rating and $72 price target (10.1% upside). 6 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EXPO analyst price targets range from $72 to $72, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $72 consensus represents the middle ground. Our model's $42-$88 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.